Inflation, drug pricing and reimbursement constraints to have negative impact on biopharmaceutical industry in 2023: GlobalData

GlobalData, a data and analytics company, on Monday said that inflation, coupled with drug pricing and reimbursement constraints, will put high pressure on the biopharmaceutical industry’s growth prospects in 2023. According to the analytics company, the biopharmaceutical industry has long been labeled as recession-proof, with stable demand for medicines and new treatment options acting as a protective barrier.
Read more...

;